The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 dose escalation and dose expansion study for LNCB74, a B7-H4 targeted antibody drug conjugate, as monotherapy in participants with advanced solid tumors.
 
Michael Song
No Relationships to Disclose
 
Anthony Tolcher
Employment - Next Oncology
Leadership - Next Oncology
Stock and Other Ownership Interests - Immunome; Pyxis (Inst)
Consulting or Advisory Role - AbbVie (Inst); Aclaris Therapeutics (Inst); Adagene (Inst); Affinia Therapeutics (Inst); Agenus (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bright Peak Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo, Inc. (Inst); Deka Biosciences (Inst); Elucida Oncology (Inst); EMD Serono (Inst); Exelixis (Inst); Gilde Healthcare (Inst); HBM Partners (Inst); HiberCell (Inst); IDEA Pharma (Inst); Ikena Oncology (Inst); Immuneering (Inst); Immunome (Inst); Immunomet (Inst); IMPAC Medical Systems (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Karma Oncology (Inst); Kirilys Therapeutics (Inst); Lengo Therapeutics (Inst); Lilly (Inst); Link Immunotherapeutics (Inst); Medicxi (Inst); Mekanistic Therapeutics (Inst); Menarini (Inst); Mersana (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nerviano Medical Sciences (Inst); Nested Therapeutics (Inst); Novo Nordisk (Inst); Nurix (Inst); Ocellaris Pharma (Inst); Partner Therapeutics (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Pierre Fabre (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); Qualigen Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Senti Biosciences (Inst); Singzyme Pte Ltd (Inst); SK Life Sciences (Inst); Sotio (Inst); Spirea (Inst); Sun Pharma Advanced Research Company (Inst); TheraTechnologies (Inst); Transcenta (Inst); Transgene (Inst); Trillium Therapeutics (Inst); Venus Oncology (Inst); Verastem (Inst); Vincerx Pharma (Inst); VRise Therapeutics (Inst); Zentalis (Inst); ZielBio (Inst)
Research Funding - AbbVie (Inst); ABL Bio (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aminex (Inst); Amphivena (Inst); Apros Therapeutics (Inst); Arcellx (Inst); ARMO BioSciences (Inst); Arrys Therapeutics (Inst); Artios (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Basilea (Inst); Bioinvent (Inst); Birdie (Inst); BJ Bioscience (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); CStone Pharmaceuticals (Inst); Daiichi Sankyo, Inc. (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); ImmuneOncia (Inst); Inhibrx (Inst); Innate Pharma (Inst); Janssen Research & Development (Inst); K-Group Beta (Inst); Kechow Pharma (Inst); Kiromic (Inst); Merck Sharp & Dohme (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Naturewise (Inst); NBE Therapeutics (Inst); NextCure (Inst); Nitto BioPharma (Inst); Odonate Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Qilu Puget Sound Biotherapeutics (Inst); Samumed (Inst); Seagen (Inst); Shanghai HaiHe Pharmaceutical (Inst); Spring Bank (Inst); Sunshine Guojian (Inst); Symphogen (Inst); Syndax (Inst); Synthorx (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
Expert Testimony - Immunogen
Travel, Accommodations, Expenses - Sotio (Inst)
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
Emese Zsiros
Honoraria - Merck
Consulting or Advisory Role - Merck
Research Funding - Merck
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
Joyce Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cullinan Oncology; Daiichi Sankyo; Deciphera; Eisai; Genentech/Roche; GlaxoSmithKline; LoxoLilly; Zentalis
Research Funding - 2X Oncology (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); Pfizer (Inst); Regeneron (Inst); Systimmune (Inst); Zentalis (Inst)
 
Daniel Morgensztern
Stock and Other Ownership Interests - Abbott Laboratories; Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Bayer; Bristol-Myers Squibb/Medarex; G1 Therapeutics; Johnson & Johnson/Janssen; Lilly Medical; Mirati Therapeutics; Natera; Tubulis GmbH
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Baxter (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Genprex (Inst); Heat Biologics (Inst); Hybercell (Inst); ImmunityBio (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); NeoImmuneTech (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst); Y-mAbs Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Genprex
 
Stephanie Kordahi
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Christine Nietubicz
Employment - GlycoMimetics, Inc.; NextCure
Stock and Other Ownership Interests - GlycoMimetics Inc.
Travel, Accommodations, Expenses - GlycoMimetics Inc.
 
Emilia Alina Barbu
Employment - NextCure
Stock and Other Ownership Interests - NextCure
Travel, Accommodations, Expenses - NextCure
 
Aaron Morawski
No Relationships to Disclose
 
Shannon Kahan
Employment - NextCure
Stock and Other Ownership Interests - Bayer; In8Bio; Macrogenics; Spyre Therapeutics; Spyre Therapeutics; Viking Therapeutics
Research Funding - NextCure
Travel, Accommodations, Expenses - NextCure
 
Priyanka Kothari
Employment - NextCure
Research Funding - NextCure
Travel, Accommodations, Expenses - NextCure
 
Dallas Flies
Employment - NextCure
Stock and Other Ownership Interests - NextCure
Patents, Royalties, Other Intellectual Property - Patent for compositions and methods for modulating lair signal transduction
 
Shanmugam Panneer Selvam
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Stephen Slocum
Employment - LigaChem Biosciences, Inc.
Stock and Other Ownership Interests - Angiex, Inc.; LigaChem Biosciences, Inc.
Consulting or Advisory Role - Angiex, Inc.
 
Rodrigo Ruiz-Soto
Employment - Deciphera; LigaChem Biosciences
Leadership - AntibodyChem Biosciences
Stock and Other Ownership Interests - Deciphera
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties
 
Solomon Langermann
Employment - NextCure
Stock and Other Ownership Interests - NextCure
 
Udayan Guha
Employment - NextCure Inc.; TCR2 Therapeutics
Stock and Other Ownership Interests - NextCure; TCR2 Therapeutics
 
Daruka Mahadevan
Honoraria - Caris Life Sciences; Guardant Health
Speakers' Bureau - Caris Life Sciences; Guardant Health
Travel, Accommodations, Expenses - Caris Life Sciences; Guardant Health